Inhibition of Cyclic AMP-triggered Aromatase Gene Expression in Human Choriocarcinoma Cells by Antisense Oligodeoxynucleotide

Karin Ackermann, Jürgen Fauss, and Walter Pyerin

Biochemical Cell Physiology, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany

ABSTRACT

Aromatase, an endomembrane-bound cytochrome P450, is the key enzyme of estrogen biosynthesis. Aromatase inhibitors, therefore, are clinically important tools in the treatment of estrogen-dependent tumor growth. To improve the specificity of these tools, inhibition at the nucleic acid level was examined. An antisense oligodeoxynucleotide complementary to the translation start region of human aromatase transcripts (antisense-arom) was synthesized and used to inhibit cyclic AMP-triggered aromatase gene expression in a human choriocarcinoma cell line (JEG-3), both as occurring in an autocrine fashion by secreted human chorionic gonadotropin or as induced by application of the membrane-permeating dibutyl cyclic AMP. Significant inhibition was obtained in both cases, reaching 70% and 60%, respectively. In addition, the antisense-arom treatment led to accelerated mRNA degradation. The inhibition at the nucleic acid level was accompanied by a decrease of both the aromatase protein and microsomal aromatase activity. The data appear to indicate the antisense strategy to be a most promising approach for the development of a novel type of specific aromatase inhibitor.

INTRODUCTION

Estrogens are growth factors for a number of tumors, particularly those of ovaries, endometrium, and breast (1). Consequently, inhibitors of estrogen biosynthesis are among the therapeutic tools of clinical oncologists. In order to sharpen these tools, further detailed studies, both of the estrogen generating system at the molecular and cellular level and the applicability of novel strategies of inhibition, are of utmost importance.

Estrogens are generated solely by an enzyme termed aromatase. The term expresses the essence of the catalyzed reaction, the conversion of androgens to estrogens due to aromatization of ring A of the steroid ring system. The aromatization is the consequence of oxidative removal of the angular C-19 methyl group. As a member of the cytochrome P450 superfamily (2), a family of endomembrane-bound monoxygenases (EC 1.14.14.1) inserting oxygen atoms into diverse hydrophobic substrates with the simultaneous consumption of reducing equivalents, aromatase introduces oxygen atoms into this methyl group in three successive steps, eventually resulting in its release as formiate (3).

Tissue aromatase activity and tumor growth have been reported to correlate in cases such as breast cancer (4) or prostate cancer (5). More directly, a correlation has been demonstrated in cell cultures. A human mammary carcinoma cell line devoid of aromatase and non-responsive to androgens as proliferation stimuli developed increased proliferation in the presence of androgens when transfected with an aromatase expressing vector. Addition of an aromatase inhibitor prevented the proliferation increase (6, 7).

Aromatase is located at the endoplasmic reticulum of estrogen-producing cells (8) receiving reducing equivalents (mainly) from NADPH-cytochrome P450 reductase, a ubiquitous FMN- and FAD-requiring protein (9). The clinically applied aromatase inhibitors are exclusively designed for binding to the enzyme protein. This approach may fall short of the mark. Other members of the P450 superfamily may also react, resulting in severe side effects. For example, the P450arom3 inhibitor aminoglutethimide also acts significantly on P450ccc, the enzyme responsible for cleavage of the cholesterol side chain. As a consequence, generation of pregnenolone, the mother compound of all steroid hormones, is inhibited (10). To avoid such effects, the inhibitor design must be based on structural motifs strictly unique for aromatase; therefore, considerations should include the nucleic acid level. At this level, powerful possibilities such as the antisense strategy may be applied. This strategy is aimed at hybrid formation of antisense molecules with single-stranded nucleic acids. Gene transcripts can specifically be trapped and their biological activity altered; hybridization of mRNAs with antisense molecules blocks translation and, as a consequence, leads to a decrease of the proteins they are coding for. Inhibition of one copy of mRNA will theoretically be much more efficient than inhibiting a protein, since one mRNA gives rise to multiple protein copies (11, 12). The unraveling of the aromatase gene and its transcripts over the past several years enables application of this approach.

The human aromatase gene (CYP 19) has a peculiar structure. It spans more than 76 kilobases and contains 9 coding exons, exon II-X (13-15). Exon I is noncoding and unusually variable. Several exons I, exon I.1 through exon I.4, have been found whose transcripts are alternatively spliced to exon II. As a consequence, the resulting aromatase mRNAs contain the same coding region but variable 5' untranslated regions. Each of the exons I appears to have its own promoter (P I.1 through P I.4) responsible for the tissue-specific expression of the different aromatase mRNA species. In addition, a promoter contiguous to exon II exists, promoter P II (16).

A variety of factors can trigger aromatase gene promoter activation and cause aromatase induction, a typical feature of the cytochrome P450 superfamily (17). These include adenylate cyclase stimulators such as the follicle-stimulating hormone, luteinizing hormone, or hCG and, consequently, membrane-permeating analogues of cAMP such as dbcAMP. Others are glucocorticoids, phorbol esters, undefined serum factors, etc. These may potentiate or inhibit each other’s effects. On the other hand, factors belonging to the growth factor family have been shown to inhibit (18).

For examination of aromatase gene expression and its inhibition at the nucleic acid level, a suitable cell culture model is required, ideally a model that constitutively shows measurable expression of aromatase and, in particular, has preserved the characteristic of aromatase induction. On screening a large number of cell types in culture, it turned out that a human choriocarcinoma cell line, JEG-3, meets the requirements. This cell line originates from a choriocarcinoma fragment
(Erwin-Turner tumor; Ref. 19), i.e., of the mesoderm-covered trophoblast, and is hypertriplid with a mean chromosome number of 71 and a moderate degree of differentiation. The cells have kept many properties of the normal trophoblast such as the synthesis of placental steroid hormones including estrogens. JEG-3 cells have been characterized already in some detail, and aromatase has been found to be regulated at the mRNA level. mRNA generation, when induced via the cAMP signaling pathway, is mediated by cycloheximide-sensitive elements, probably labile protein(s) including RNA stabilizing protein(s) (20, 21). This expression regulation at the mRNA level is a particularly favorable condition for affecting induction of aromatase by the antisense approach.

We show here that aromatase mRNA and, as a result, aromatase protein and aromatase activity are significantly decreased by synthetic antisense oligodeoxynucleotide directed against aromatase transcripts when aromatase gene expression is stimulated via the cAMP signaling pathway. The antisense molecules were designed for an interaction with the translation start region, a strategy already successfully applied in different biological systems (11, 12, 22, 23), including our effort to define a role of a protein kinase, casein kinase II, in the mitogenic signaling of cells (24, 25). Furthermore, this strategy should be applicable to any of the aromatase transcripts independent of tissue-specific use of the various aromatase gene promoters, because the translation start is in exon II, and exon II is present in all of the different aromatase transcripts generated in different tissues. In order to arrive at these results, the expression of aromatase in JEG-3 cells via the cAMP signaling pathway had to be characterized. These data suggest an autocrine expression mechanism mediated by hCG and, on the other hand, provided the necessary chronological details of aromatase induction by dbcAMP to allow for examination of antisense oligodeoxynucleotide effects.

MATERIALS AND METHODS

Cell Culture

JEG-3 cells, obtained from American Type Culture Collection (HTB36), were grown in Eagle’s minimum essential medium (GIBCO) supplemented with 10% FCS (GIBCO) at 37°C in a 95% air and 5% CO₂ atmosphere. In cases of serum-free propagations, cells were cultured in the presence of serum until reaching subconfluency. Then the medium was changed to serum-free Eagle’s minimum essential medium and incubation continued. Cells were harvested by scraping off in phosphate-buffered saline and sedimented by centrifugation at 800 X g. When not analyzed immediately, cell pellets were stored at —80°C until use. Cell numbers were determined using a Coulter Counter (Coulter Electronics, Krefeld, Germany). To induce aromatase, cells were grown in Eagle’s minimum essential medium and incubation continued. Cells were disrupted by sonification, and microsomes were obtained in two steps by centrifugation of the homogenate at 10,000 x g for 20 min and of the resulting supernatant at 300,000 x g for 20 min. All operations were performed at 4°C. Human placental microsomes were obtained as described previously (27).

Preparation of Microsomes

Cell pellets were resuspended in homogenization buffer, pH 7.4 (10 mM potassium phosphate, 150 mM KCl, and 10 mM EDTA). Cells were disrupted by sonification, and microsomes were obtained in two steps by centrifugation of the homogenate at 10,000 x g for 20 min and of the resulting supernatant at 300,000 x g for 20 min. All operations were performed at 4°C. Human placental microsomes were obtained as described previously (27).

Determination of Aromatase Activity

HPLC Assay. After washing, microsomal pellets were carefully resuspended in reaction buffer, pH 7.4, containing 50 mM potassium phosphate, 2.5 mM glucose-6-phosphate, 0.25 units/ml glucose-6-phosphate dehydrogenase, and 10 μM androstenedione or testosterone as substrate. The mixture was preincubated at 37°C for 5 min, and the reaction was started by adding NADPH to a final concentration of 100 μM. After 5 h, the reaction was stopped by adding dichloromethane in a 1:1 volume, and the steroids were extracted. Then the organic phase was removed under vacuum, and the dried samples were redisolved in 20 μl of 40% acetonitrile. After a short centrifugation in order to pellet insoluble components, the supernatant was injected into the HPLC apparatus. Analysis was carried out according to Taniguchi et al. (27) by reverse phase-HPLC using a Spherisorb ODS-2 column (4.6 x 50 mm, 3-μm particle; Pharmacia, Freiburg, Germany) with the modifications described recently (28) using monitoring by photodiode array detector (Waters 991, Millipore, Milford, MA). The product formation was calculated on basis of defined amounts of estrogens added prior to the extraction and by using the employed substrate amounts as internal standards.

ELA. Microsomes were incubated in the presence of testosterone (10 μM) as the substrate as described for the HPLC assay. The reaction was stopped by heating to 95°C for 5 min and the formation of E2 was determined by a competitive E2-enzyme immunoassay kit (Dianova, Hamburg, Germany).

Secretion of E2. Media of cell cultures were extracted with diethyl ether. The concentration of E2 was determined after evaporation of organic phase under N₂ by using the enzyme immunoassay described above or a radi-immunoassay kit (Seronova, Freiburg, Germany).

Western Blot Analysis

Microsomes were resuspended in homogenization buffer and separated by the Laemmli gel electrophoresis using 12% polyacrylamide gels in the presence of 2% sodium dodecyl sulfate (SDS-PAGE). Protein (70–100 μg) was
mixed with SDS sample buffer [50 mM Tris-HCl (pH 6.8) containing 10% glycerol, 2% SDS, 0.2% dithiothreitol, and 0.002% bromophenol blue], separated by SDS-PAGE, and transferred to a PVDF membrane (Immobilon P; Millipore) by semidy blotting (Trans-blot SD; Bio-Rad, Munich, Germany). Transferred proteins were stained with 0.3% Ponceau S in 3% trichloroacetic acid and destained in water. After incubation with blocking solution [10 mM Tris-HCl (pH 7.4), 10% dry milk, 1% bovine serum albumin, 0.3% Tween 20, and 150 mM NaCl], the membrane was incubated with a monospecific rabbit polyclonal antibody (1:5000) raised against human placental aromatase (27). Detection of bound antibody was performed by goat anti-rabbit IgG conjugated to peroxidase (1:2000; Dianova) and visualization with o-dianisidine.

**Protein Assay.** Protein concentrations were measured according to the method of Bradford (29) using bovine serum albumin as a standard.

**Determination of hCG Secretion.** Media of cell cultures were collected, and the concentration of hCG was determined with an enzyme immunoassay kit using two monoclonal antibodies against the β subunit of hCG (DDV Diagnostica, Marburg, Germany).

**RESULTS AND DISCUSSION**

**Aromatase Expression in the JEG-3 Cell Model System.** JEG-3 cells started colonization 1 day after seeding, followed by formation of cell islands after 2 days, subconfluency after 3 days, and, finally, confluency after 4 days, indicating a generation time of roughly one day (Fig. 1A). The generation time varied somewhat with the passage number of cells; roughly 17 and 26 h were determined as generation times for cells of passages 5 and 35, respectively (Fig. 1B). Other choriocarcinoma cell lines such as HM, HCCM-5, or NUC-1 have generation times of up to 48 h (30). The relatively short generation time aside, further experimental advantages of JEG-3 cells are their reasonably effective uptake of foreign DNA, of importance for experiments with antisense oligodeoxynucleotides, and their relatively constant cell physiological behavior when compared to that of primary culture systems such as adipose cells or granulosa cells frequently used in aromatase investigations. With the latter, reproducibility of results in our hands was rather poor because of low cell yields and significant donor-dependent variabilities.

The estrogen biosynthesis of JEG-3 cells is mediated by aromatase gene transcripts 3.4 and 2.9 kilobases in length (Fig. 1C, inset). This is as expected since two alternatively used polyadenylation sites occur in the gene (13). The two mRNA species are also found in human placenta and other aromatase-positive tissues and cells in culture (31). The 3.4-kilobase mRNA represents, by far, the more abundant form. The ratio of the two mRNA species appears to be rather stable and
Fig. 2. Secretion of hCG by JEG-3 cells in comparison to expression and activity of aromatase. After reaching subconfluency in the presence of FCS, incubation of cells was continued under serum-free conditions for the indicated times. A, secretion of hCG (E1) was determined by EIA based on antibodies specific for α-hCG. Microsomal aromatase activity (C) was determined by incubation of resuspended post-nuclear 100,000 × g pellets in the presence of testosterone followed by E2-EIA. Expression of aromatase mRNA (insert) and secretion of E2 (O) were determined as described in the legend to Fig. 1C. Bar, SD. B, Western blot. Microsomal aromatase protein was assessed by SDS-PAGE separation of microsomal proteins (70 μg each), transfer to PVDF membrane, and identification of aromatase protein by monospecific polyclonal aromatase antibody with o-dianisidine/peroxide staining reaction coupled to the second antibody. Microsomes of human placenta (5 μg protein) were used as a positive aromatase control (Pl, arrowhead). Bottom line, incubation of JEG-3 cells in the absence (−) or presence (+) of 1 mM dbcAMP and times of cell harvesting after dbcAMP addition. Positions of M, marker proteins are given on the right.

independent of the level of total aromatase mRNA in JEG-3 cells and also of the signaling pathway by which the aromatase gene expression has been triggered. In addition, JEG-3 cells express a 1.6-kilobase aromatase mRNA species. Although at a comparably very low level, this species is observed consistently and has also been described in another recent article on JEG-3 aromatase (21). The aromatase mRNA level in JEG-3 cells increased with increasing cell density, reaching a plateau at confluency (Fig. 1C). In parallel, there was accumulation of secreted E2 in the cell medium. However, when calculating the secreted E2/10^6 cells, lag phase cells (cells at 1-day post-seeding) and confluent cells (cells at 4–5 days post-seeding) secreted the 1.5- to 2-fold E2 amount of log phase cells (Fig. 1C). Thus, there is a reverse correlation of the proliferation and estrogen synthesis of cells confirming the general suppression of differentiation-dependent hormone synthesis during cell growth (30).

While aromatase mRNA is constitutively expressed in JEG-3 cells, other members of the cytochrome P450 superfamily are not. Using specific probes for members of family 1 (CYP1A1), family 2 (CYP2B6, 2C9, and 2D6), and family 3 (CYP3A4) in Northern blots, no signals were obtained (data not shown). This is of some interest because a number of cis-acting elements are present in the promoters of these P450 genes, which also occur in the P450arom promoters (2).

The subconfluent state turned out to be that most suited for a change to serum-free conditions, a prerequisite for reliable studies on aromatase expression and its modulation. This is because serum significantly and uncontrollably affects aromatase expression. When determined 24 h after changing to serum-free medium, the level of aromatase mRNA in JEG-3 cells showed significant differences in dependence on the serum preparation used, and there were differentially strong memory effects on aromatase induction; in the presence of different serum preparations, we observed inhibition of aromatase induction by growth factor addition in one experiment but even stimulation in another (data not shown). Thus, the set of experiments shown here has strictly been based on the use of one and the same
Arrows pointing downwards, times of successive application of antisense oligodeoxynucleotides; bent arrow, time of cell harvesting and determination of antisense effect on aromatase expression (see Figs. 5 and 6).

Fig. 3. Kinetics of aromatase induction by dbcAMP in JEG-3 cells. JEG-3 cells, having reached subconfluency in the presence of serum, were kept serum-free for 24 h before 1 mM dbcAMP was added and incubation continued. At the time of dbcAMP addition or at the indicated times after that, aromatase mRNA (●) and microsomal aromatase activity (□) were determined as described in the legends to Fig. 1C and Table 1, respectively; bars, SD. Values obtained in the presence of dbcAMP were compared to values obtained in parallel experiments in the absence of dbcAMP at each time point (controls). Note that the increase in aromatase mRNA level precedes that of aromatase activity (shaded area). Arrows pointing downwards, times of successive application of antisense oligodeoxynucleotides, bent arrow, time of cell harvesting and determination of antisense effect on aromatase expression (see Figs. 5 and 6).

Table 1 Induction of aromatase by dbcAMP in the absence and presence of serum

<table>
<thead>
<tr>
<th>Serum present</th>
<th>dbcAMP stimulated</th>
<th>Aromatase activitya</th>
<th>Stimulation factorb</th>
</tr>
</thead>
<tbody>
<tr>
<td>no</td>
<td>no</td>
<td>13 ± 3</td>
<td>4.1</td>
</tr>
<tr>
<td>no</td>
<td>yes</td>
<td>30 ± 6</td>
<td>2-3</td>
</tr>
<tr>
<td>yes</td>
<td>no</td>
<td>8 ± 2</td>
<td>7-8</td>
</tr>
<tr>
<td>yes</td>
<td>yes</td>
<td>62 ± 22</td>
<td></td>
</tr>
</tbody>
</table>

a pmol estrogen formed per 5 h and mg microsomal protein
b Ratio of microsomal aromatase activity of dbcAMP-stimulated cells and non-stimulated cells

Fig. 4. Oligodeoxynucleotide-targeted P45Oarom transcript sequence. Antisense 5' to 20 oligodeoxynucleotide (antisense-arom) and sense 5' to 3' oligodeoxynucleotide (sense-arom), 20 nucleotides in length, were synthesized covering the translation initiation site ATG (underlined) in exon II of human P450arom transcripts. In addition, three mutations were introduced into antisense-arom marked by stars (mutated antisense-arom). Numbers on top, nucleotide positions in aromatase transcripts.

serum preparation and transfer to serum-free conditions 24 h before applying aromatase modulators. Interestingly, the aromatase expression also increased with time under serum-free conditions.

Autocrine Induction of Aromatase by hCG? The increase of aromatase expression in the absence of serum was noted upon determination of aromatase mRNA, of microsomal aromatase activity, and of secreted E2 (Fig. 2A). The results could be explained in different ways; for instance, by leaky aromatase promoters or by the production of factor(s) by JEG-3 cells which can affect expression of the aromatase gene in an autocrine fashion. The latter appears to be the case. hCG was found to be released into cell medium. This peptide hormone consists of a small subunit identical to follicle-stimulating hormone, luteinizing hormone, and thyroid-stimulating hormone and a unique β subunit. It binds to surface receptors and transmits its message intracellularly via cAMP (32). When JEG-3 cells were cultivated under serum-free conditions, increasing amounts of hCG were measured in the cell medium with time, and the secreted amounts of hCG paralleled the increases in microsomal aromatase activity (Fig. 2A). hCG has already been shown to induce aromatase (33). Concomitantly to hCG release, there was also the expected increase of microsomal aromatase protein (Fig. 2B; minus dbcAMP). This autocrine induction mechanism is reminiscent of the situation in estrogen-dependent tumor tissues that autonomously produce their own growth stimulus (4).

Aromatase Expression Is Strongly Induced by dbcAMP. The intracellular cAMP increase due to peptide hormones such as secreted hCG was mimicked with the membrane-permeating cAMP derivative dbcAMP. When dbcAMP was added to the medium of JEG-3 cells, aromatase was induced significantly. Addition of dbcAMP to the medium of confluent cells kept under serum-free conditions increased the specific microsomal aromatase activity 2-3-fold above constitutive levels (Table 1). Again, serum had a strong impact. In the presence of serum, dbcAMP addition resulted in a 7-8-fold increase of aromatase.

The kinetics of aromatase induction by dbcAMP is shown in Fig. 3. Following a period of moderate increase (below 1.5-fold), the increase in microsomal aromatase activity was accelerated significantly at 18-20 h post induction. While activity at 18 h post induction was still at 1.5-fold the level of controls, this was increased to nearly 4-fold that of controls at 24 h. The increase in microsomal aromatase activity was accompanied by an increase of microsomal aromatase protein (Fig. 2B; plus dbcAMP). The induction characteristic of aromatase mRNA was shaped similarly to that of aromatase activity. However, the acceleration of mRNA increase occurred roughly 2 h prior to that of microsomal aromatase activity. This nicely meets the chronological and biochemical expectations of an induction process controlled at the mRNA level. The induction characteristic also provided a reliable basis for the set up of experiments with the antisense aromatase molecules, an approach to inhibition of cellular aromatase that has not yet been described.

Antisense Aromatase Oligodeoxynucleotide Specifically Inhibits Aromatase Expression. A 20-mer antisense-arom was synthesized complementary to position 36-55, the translation start region of human aromatase mRNA (Fig. 4). As controls, antisense-arom carrying mutations at three positions and the respective sense oligodeoxynucleotide were prepared. This aromatase sequence was chosen as the target because it contains rare nucleotide combinations, in particular an AAAACC box (position 43-48), and, most importantly, because it is located within exon II. Since the effect of unmodified antisense oligodeoxynucleotides arises primarily from hybridization with transcripts and their translation inhibition, and since exon II represents a constant part of all of the P450arom mRNAs, the antisense construct should affect any aromatase induction independent of tissue-specific activation of the diverse exon I promoters and the following splicing events. For application of antisense-arom, the relatively small window of accelerated aromatase mRNA increase

4944
prior to the acceleration of microsomal aromatase activity increase was chosen (Fig. 3, shaded area). Unmodified antisense oligodeoxynucleotides such as those used here usually have short half-lives (34). However, deoxyribonucleotides have a greater stability than oligoribonucleotides (11). Thus, a repeated application was performed, and the cells were analyzed for aromatase 6 h after the last application (Fig. 3, arrows). The concentration used was in the range of 16 μM antisense-arom, a range that had been calculated to be effective in our previous work with antisense oligodeoxynucleotides (24, 25). A concentration of 5–200 μM is the suggested range for antisense oligodeoxynucleotide experimentation in general (22). No apparent toxicity is observed at this range. Only a small portion appears to become available in the cytoplasm, probably because the majority is degraded in lysosomes (35). This is the reason for the application of such a relatively high concentration of oligodeoxynucleotides.

![Diagram](image)

**Fig. 5.** Effect of antisense-arom on expression of P450arom-mRNA. A, Northern blot. JEG-3 cells were incubated in the absence of dbcAMP (untreated cells; C) and in the presence of dbcAMP (stimulated cells; S) for 14 h. Then, antisense-arom (100 μg/ml) was added to untreated (C,as) and stimulated (S,as) cells. Antisense-arom addition was repeated at 16 and 18 h after dbcAMP application. At 24 h after dbcAMP application, cells were harvested and analyzed in duplicates for aromatase mRNA expression by Northern blotting (12 μg total RNA each) using radiolabeled specific arom probe (a). The filters were reprobed for GAPDH as a control (b). Indicated are the different aromatase transcripts (see Fig. 1C, inset) and degradation products (arrowhead). The regimen of treatment and harvesting of cells is indicated in Fig. 3 by arrows. B, densitometric quantitation. Autoradiographic signals of aromatase mRNA shown in (A) were normalized to that of GAPDH-mRNA, set at 100% in cases without antisense treatment (C, S, □), and compared to the signals obtained in antisense-arom treated cells (C,as, S,as, ■); bars, SD.

![Graph](image)

**Fig. 6.** Effect of antisense-arom on microsomal aromatase activity and aromatase protein. A, microsomal aromatase activity. After 24 h in the absence of serum, dbcAMP was added to JEG-3 cells, followed 14, 16, and 18 h later by a treatment with antisense-arom (S,as) as described in the legend to Fig. 5 or remained without antisense-arom (S). Twenty-four h after dbcAMP addition, cells were harvested, and microsomal aromatase activity was determined as described in the legend to Fig. 2A. Shown are the means of four independent experiments; bars, SD. The value obtained without antisense treatment was set at 100%. B, microsomal aromatase (Western blot). Microsomal protein (70 μg) was separated by SDS-PAGE, transferred to PVDF membrane, and analyzed as described in Fig. 2B.

When antisense-arom was applied at 14, 16, and 18 h post application of dbcAMP and the cells were harvested at 24 h, aromatase induction in JEG-3 cells was significantly inhibited. The level of aromatase mRNA measured at 24 h post stimulation was decreased by roughly 60% (Fig. 5). In addition, an accelerated degradation of aromatase mRNA was noted. Antisense-mediated mRNA destabilization was also observed in other cases and explained by endonuclease activity specifically targeting mRNA in DNA/RNA hybrids (12). Neither decreased aromatase mRNA nor RNA degradation was seen in cells treated with the sense-arom or the mutated antisense-arom or in cells without oligodeoxynucleotide treatment. Furthermore, the antisense-arom effect was neutralized upon simultaneous application of sense-arom (data not shown). Interestingly, not only was the dbcAMP-triggered aromatase mRNA increase inhibited by antisense-arom, but inhibition was also noted for the autocrine aromatase stimulation. In this case, the decrease of aromatase mRNA was roughly 70% and was also accompanied by accelerated degradation of arom-mRNA.

The effect of antisense-arom was determined 6 h after the last application. One would necessarily expect, therefore, that the detected decrease of the arom mRNA level would also have led to a decreased cellular aromatase. This was, in fact, the case. Significant decreases of both the specific microsomal aromatase activity and the microsomal aromatase protein were observed (Fig. 6). Both decreases matched in extent the decrease in mRNA.

The data appear to verify the hypothesis that expression of the human aromatase gene should be sensitive to inhibition by the antisense strategy. The results suggest that the aromatase antisense oligodeoxynucleotide used is taken up by JEG-3 cells, hybridizes with aromatase mRNAs, and, as a consequence, prevents translation into aromatase protein, resulting in decreased cellular aromatase levels. In addition, the hybridization seems to cause accelerated degradation of aromatase mRNA, amplifying the antisense effect. The high specificity of the antisense approach for an aromatase-coding structure warranted the hope that the antisense strategy may become a highly useful tool for aromatase inhibition and eventually find clinical application.
ACKNOWLEDGMENTS

We thank Prof. V. Kinzel, German Cancer Research Center, for encouragement; Dr. J. Reed, German Cancer Research Center, for semantic help; and Drs. R. Wolf and C. J. Henderson, University of Dundee, for providing specific cDNA probes for P450 species of families I, II, and III. The contributions to some experiments by C. Schreckenberger and U. Wirkner are acknowledged.

REFERENCES

Inhibition of Cyclic AMP-triggered Aromatase Gene Expression in Human Choriocarcinoma Cells by Antisense Oligodeoxynucleotide

Karin Ackermann, Jürgen Fauss and Walter Pyerin


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/54/18/4940

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.